Compound Summary
Compound Information
bumetanide
Compound Name: | bumetanide |
Compound CID: | 2471 |
Synonyms: | bumetanide 28395-03-1 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid Bumex Burinex More... |
Iupac Name: | 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid |
InChI: | InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23) |
InChIKey: | MAEIEVLCKWDQJH-UHFFFAOYSA-N |
Canonical Smiles: | CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2 |
Isomeric Smiles: | CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2 |
Molecular Weight: | 364.4 |
Molecular Formula: | C17H20N2O5S |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
bumetanide
Molecular Weight: | 364.4 |
Molecular Formula: | C17H20N2O5S |
Hydrogen Bond Donor Count: | 3 |
Hydrogen Bond Acceptor Count: | 7 |
Rotatable Bond Count: | 8 |
Heavy Atom Count: | 25 |
Complexity: | 528 |
Synonyms
bumetanide
| bumetanide | bumetanide |
|---|---|
bumetanide |
28395-03-1 |
3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid |
Bumex |
Burinex |
Fordiuran |
Lunetoron |
Fontego |
Segurex |
Ro 10-6338 |
Bumetanida |
Bumetanidum |
Bumetanidum INN-Latin |
3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid |
Bumetanida INN-Spanish |
PF 1593 |
Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy- |
UNII-0Y2S3XUQ5H |
C17H20N2O5S |
0Y2S3XUQ5H |
MLS000028457 |
CHEBI:3213 |
Aquazone |
Butinat |
Cambiex |
Diurama |
Yurinex |
BENZOIC ACID, 3-(BUTYLAMINO)-4-PHENOXY-5-SULFAMOYL- |
Burine |
3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid |
3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid |
Lixil-Leo |
MFCD00078949 |
NCGC00015149-02 |
SMR000058418 |
Lixil |
CAS-28395-03-1 |
Ro 10-6338;PF 1593 |
DSSTox_CID_2699 |
3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid |
DSSTox_RID_76695 |
DSSTox_GSID_22699 |
Bufenox |
Bumex (TN) |
SR-01000003062 |
EINECS 249-004-6 |
BRN 2185351 |
Bumetanide (Ro 10-6338) |
Prestwick_679 |
Bumetanide USAN:USP:INN:BAN:JAN |
Ro-10-6338 |
Spectrum_001317 |
Bumetanide, >=98% |
Opera_ID_1734 |
Prestwick0_000276 |
Prestwick1_000276 |
Prestwick2_000276 |
Prestwick3_000276 |
Spectrum2_001050 |
Spectrum3_001481 |
Spectrum4_000030 |
Spectrum5_001212 |
Lopac-B-3023 |
B 3023 |
cid_2471 |
CHEMBL1072 |
Lopac0_000162 |
SCHEMBL27525 |
BSPBio_000152 |
BSPBio_001508 |
BSPBio_003061 |
KBioGR_000228 |
KBioGR_000439 |
KBioSS_000228 |
KBioSS_001797 |
3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoic acid |
MLS001148265 |
DivK1c_000034 |
SPECTRUM1502004 |
SPBio_000980 |
SPBio_002371 |
BPBio1_000168 |
Bumetanide (JP17/USP/INN) |
GTPL4837 |
DTXSID5022699 |
BDBM25903 |
HMS500B16 |
KBio1_000034 |
KBio2_000228 |
KBio2_001797 |
KBio2_002796 |
KBio2_004365 |
KBio2_005364 |
KBio2_006933 |
KBio3_000455 |
KBio3_000456 |
KBio3_002561 |
NINDS_000034 |
3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid |
Bio1_000421 |
Bio1_000910 |
Bio1_001399 |
Bio2_000228 |
Bio2_000708 |
HMS1361L10 |
HMS1568H14 |
HMS1791L10 |
HMS1921B20 |
HMS1989L10 |
HMS2089P13 |
HMS2092N03 |
HMS2095H14 |
HMS2230P15 |
HMS3259O08 |
HMS3260B05 |
HMS3374E02 |
HMS3402L10 |
HMS3654B13 |
HMS3712H14 |
HMS3873C13 |
Pharmakon1600-01502004 |
BCP28485 |
ZINC3813061 |
Tox21_110088 |
Tox21_500162 |
CCG-40125 |
NSC758145 |
s1287 |
AKOS015896600 |
Tox21_110088_1 |
AC-8115 |
CS-1821 |
DB00887 |
KS-5211 |
LP00162 |
MCULE-6802013568 |
NC00550 |
NSC 758145 |
NSC-758145 |
Ro-106338 |
SDCCGSBI-0050150.P004 |
IDI1_000034 |
IDI1_033978 |
SMP1_000049 |
NCGC00015149-01 |
NCGC00015149-03 |
NCGC00015149-04 |
NCGC00015149-05 |
NCGC00015149-06 |
NCGC00015149-07 |
NCGC00015149-08 |
NCGC00015149-09 |
NCGC00015149-10 |
NCGC00015149-11 |
NCGC00015149-12 |
NCGC00015149-13 |
NCGC00015149-15 |
NCGC00015149-16 |
NCGC00015149-26 |
NCGC00022072-03 |
NCGC00022072-04 |
NCGC00022072-05 |
NCGC00022072-06 |
NCGC00022072-07 |
NCGC00022072-08 |
NCGC00260847-01 |
HY-17468 |
SBI-0050150.P003 |
AB0012138 |
AB00052253 |
EU-0100162 |
ST51014910 |
SW196834-3 |
D00247 |
J10080 |
3-butylamino-4-phenoxy-5-sulphamyl-benzoic acid |
AB00052253-15 |
AB00052253-16 |
AB00052253_17 |
AB00052253_18 |
3-n-butylamino-4-phenoxy-5-sulfamyl-benzoic acid |
3-n-butylamino-4-phenoxy-5-sulphamyl-benzoic acid |
395B031 |
A819434 |
Q275926 |
S95008. |
J-017055 |
S-95008. |
SR-01000003062-2 |
SR-01000003062-4 |
SR-01000003062-7 |
BRD-K38197229-001-06-7 |
BRD-K38197229-001-17-4 |
Z1550648769 |
Bumetanide, British Pharmacopoeia (BP) Reference Standard |
Bumetanide, European Pharmacopoeia (EP) Reference Standard |
Bumetanide, United States Pharmacopeia (USP) Reference Standard |
Ro 10-6338; PF 1593 pound>>Ro-10-6338; PF1593 pound>>Ro10-6338; PF-1593 |
Experimental Data
bumetanide
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33 | umol/L | -6 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
bumetanide
Statistics Data
bumetanide
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -6 | 1 | 1 |
Statistics Data Visualization
bumetanide
